Sulfonylurea receptor 1 gene variants are associated with gestational diabetes and type 2 diabetes but not with altered secretion of insulin.

J Rissanen, A Markkanen, P Kärkkäinen… - Diabetes …, 2000 - Am Diabetes Assoc
J Rissanen, A Markkanen, P Kärkkäinen, J Pihlajamäki, P Kekäläinen, L Mykkänen…
Diabetes Care, 2000Am Diabetes Assoc
OBJECTIVE: To investigate the possible association of the variants in the nucleotide binding
fold regions of the sulfonylurea receptor 1 (SUR1) gene with gestational diabetes mellitus
(GDM), type 2 diabetes, and altered insulin secretion in Finnish subjects. RESEARCH
DESIGN AND METHODS: The nucleotide binding fold regions of the SUR1 gene were
amplified with polymerase chain reaction and screened by the single-strand conformational
polymorphism analysis in 42 subjects with GDM and 40 subjects with type 2 diabetes …
OBJECTIVE
To investigate the possible association of the variants in the nucleotide binding fold regions of the sulfonylurea receptor 1 (SUR1) gene with gestational diabetes mellitus (GDM), type 2 diabetes, and altered insulin secretion in Finnish subjects.
RESEARCH DESIGN AND METHODS
The nucleotide binding fold regions of the SUR1 gene were amplified with polymerase chain reaction and screened by the single-strand conformational polymorphism analysis in 42 subjects with GDM and 40 subjects with type 2 diabetes. Detected variants were further investigated in 377 normoglycemic subjects by restriction fragment-length polymorphism analysis. The effect of the variants of the SUR1 gene on first-phase insulin secretion was studied in 295 normoglycemic subjects.
RESULTS
In subjects with GDM or type 2 diabetes, one amino acid change (S1369A), four silent substitutions (R1273R, L829L, T759T, and K649K), and three intron variants were identified in the nucleotide binding fold regions of the SUR1 gene. A tagGCC allele of exon 16 splice acceptor site was more frequent in subjects with GDM (0.55 allele frequency, n = 42) and type 2 diabetes (0.60, n = 40) than in normoglycemic subjects (0.43, n = 377) (P1 = 0.024 and P2 = 0.009, respectively). Similarly, an AGG allele of the R1273R polymorphism was more common in subjects with GDM (0.87) and type 2 diabetes (0.87) than in normoglycemic subjects (0.74) (P1 = 0.009 and P2 = 0.001, respectively). However, the S1369A, R1273R, and cagGCC-->tagGCC variants of the SUR1 gene were not associated with altered first-phase insulin secretion in 295 normoglycemic subjects.
CONCLUSIONS
These results suggest that a functional variant that contributes to the risk of GDM and type 2 diabetes may locate close to the SUR1 gene.
Am Diabetes Assoc